Trials / Unknown
UnknownNCT06273878
From Fetal-maternal Interface Immune Tolerance to Endometrial Cancer Immune Escape: Potential Targets for Immunotherapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Regina Elena Cancer Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional retro-prospective study on Endometrial tissue samples taken from surgically treated patients.
Detailed description
The picture of precisely coordinated immune adaptations over time at the maternal-fetal interface level and altered in pregnancy complications, could reveal a specific "immune clock" in tumors. The study aims to decipher mechanisms of immunodeficiency by helping to predict recurrence in patients with endometrial cancer and identify molecular pathways that are turned on or off in progression from lesions early to advanced neoplasia. This will allow the discovery of potential immunotherapy targets to interfere with the immune escape activation process or to reactivate/re-educate the immune response.
Conditions
Timeline
- Start date
- 2023-01-15
- Primary completion
- 2025-01-15
- Completion
- 2025-01-15
- First posted
- 2024-02-23
- Last updated
- 2024-02-23
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06273878. Inclusion in this directory is not an endorsement.